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Although human induced pluripotent stem cells
(hiPSCs) have enormous potential in regenerative
medicine, their epigenetic variability suggests that
some lines may not be suitable for human therapy.
There are currently few benchmarks for assessing
quality. Here we show that X-inactivation markers
can be used to separate hiPSC lines into distinct
epigenetic classes and that the classes are pheno-
typically distinct. Loss of XIST expression is strongly
correlated with upregulation of X-linked oncogenes,
accelerated growth rate in vitro, and poorer differen-
tiation in vivo. Whereas differences in X-inactivation
potential result in epigenetic variability of female
hiPSC lines, male hiPSC lines generally resemble
each other and do not overexpress the oncogenes.
Neither physiological oxygen levels nor HDAC inhib-
itors offer advantages to culturing female hiPSC
lines.We conclude that female hiPSCsmay be epige-
netically less stable in culture and caution that loss
of XIST may result in qualitatively less desirable
stem cell lines.
INTRODUCTION
With the potential to differentiate into cells of three germ lineages
ex vivo, human embryonic stem cells (hESCs) hold immense
promise for the field of regenerative medicine. Their derivation
from the early human embryos has, however, limited the extent
to which hESCs can be generated tomeet the needs of an immu-
nologically diverse population. A major breakthrough, therefore,
has been creation of patient-specific hESC-like cells from
somatic cells by reprogramming through defined pluripotencyfactors OCT4, SOX2, KLF4, and c-MYC (OSKM) (Takahashi
and Yamanaka, 2006; Yu et al., 2007). These ‘‘human induced
pluripotent stem cells’’ (hiPSCs) share similar gene expression
profiles, morphologies, and differentiation potential with hESCs
(Wernig et al., 2007; Maherali et al., 2008), and mouse-derived
iPSCs can be passaged through the germline (Okita et al.,
2007). Although hiPSCs solve major ethical issues, recent
studies have revealed that they may be as genetically and epige-
netically fluid as hESCs (Kim et al., 2010; Bock et al., 2011; Gore
et al., 2011). There may also be greater expression anomalies in
hiPSCs (Rugg-Gunn et al., 2005, 2007; Adewumi et al., 2007;
Pick et al., 2009). Because mutation and epigenetic change
can lead to cancer and other diseases, these observations imply
that some hiPSC lines may not be suitable in a clinical setting.
However, apart from karyotype and a limited panel of differenti-
ation markers, there are currently few established benchmarks
for assessing hiPSC quality and suitability.
Interestingly, unlike mouse embryonic stem cells (mESCs),
hESCs vary tremendously in their potential to undergo X chromo-
some inactivation (XCI) (Hoffman et al., 2005; Adewumi et al.,
2007; Hall et al., 2008; Shen et al., 2008; Silva et al., 2008; Dvash
et al., 2010; Lengner et al., 2010), an epigenetic event that is
tightly coupled to cell differentiation both in vivo during epiblast
differentiation and ex vivo in cultured embryonic stem cells
(Payer and Lee, 2008). During XCI, one of two female X chromo-
somes is transcriptionally repressed to achieve similar X-linked
gene dosage as males. This process depends on expression
of the long noncoding Xist RNA, which is upregulated just prior
to the initiation of chromosome-wide silencing (Marahrens
et al., 1997; Wutz and Jaenisch, 2000), and results in recruitment
of repressive chromatin to the X. Whereas all XX female mESCs
faithfully recapitulate XCI in culture, female hESCs have been
grouped into three classes based on differences in their ability
to do so. Class I lines initially carry two active Xs (XaXa) but
can upregulate XIST and undergo XCI during cell differentiation,
suggesting that they most closely approximate the mESC ideal.
Class II lines already possess one inactive X (XaXi) and mayCell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc. 75
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Figure 1. Partial X Reactivation and High-Frequency Class III Conversion in Female hiPSCs
(A) RNA FISH of IMR-90 and undifferentiated hiPS-10. XIST RNA, red; Cot-1 RNA, green; asterisk, XIST cloud; arrow, COT-1 hole.
(B) RNA FISH for XIST and Cot-1, followed by X-paint DNA FISH. Arrows, Cot-1 holes; asterisk, XIST cloud; double arrowheads, X chromosomes. Shown is
hiPS-1 p.6.
(C) Immunostaining for H3K27me3 (red) followed by DNA FISH (green) for X chromosomes in differentiated (d16) hiPSCs.
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Sex Differences in hiPSCstherefore be partially differentiated. Class III lines largely already
underwent XCI but subsequently lost XIST expression, raising
questions about their epigenetic stability (Silva et al., 2008;
Dvash et al., 2010). Whether these epigenetic classes them-
selves have practical implications remains unclear. However,
because the XCI phenotype may correlate with differentiation
potential, XIST has been proposed as a benchmark for assessing
hESC quality (Silva et al., 2008).
Indeed, use of the XIST marker led to identification of more
XaXa hESCs at early passage (Dvash et al., 2010), discovery
that physiological oxygen concentrations are preferable for
deriving class I cell lines, and demonstration that stressful
ex vivo conditions are associated with conversion to the class
III epigenotype (Lengner et al., 2010). These observations have
lately generated much interest in the X chromosome status of
hiPSCs and raised the question of whether XIST could also be
used as a benchmark for hiPSC quality. In the mouse system,
reprogramming of somatic cells to iPSCs is accompanied by
X reactivation (Maherali et al., 2007). By contrast, recent studies
in the human system have reported varying results, with some
demonstrating that reprogramming does not reactivate the Xi
of parental fibroblasts (Tchieu et al., 2010; Cheung et al.,
2011), and others observing that some hiPSC lines have reacti-
vated Xi (Lagarkova et al., 2010; Marchetto et al., 2010). Unre-
solved, therefore, is whether hiPSCs ever attain the XaXa state
associated with pluripotency in the mouse system and in class
I hESCs. Also unclear is whether X chromosome states can be
used as a readout for female hiPSC quality. Below, we inves-
tigate the XCI status and implications of XCI differences in
female hiPSCs. We report genome-wide signatures associated
with loss of XIST expression and demonstrate sex-specific
differences, the combination of which caution that female
hiPSCs may be inherently more difficult to maintain by existing
protocols.
RESULTS
X Reactivation and Inactivation in Female hiPSCs
Given contrasting reports on X reactivation during establishment
of hiPSC lines, we revisited this question by following the
X-transcriptional status of new female hiPSC lines derived from
IMR-90, a diploid human fetal fibroblast line that has been
used extensively to generate hiPSCs (Yu et al., 2007). Cells
were reprogrammed using virally expressed OSKM (Park et al.,
2008a) and colonies picked between days 28 and 32 (Figure S1A
available online). Immunostaining (Figure S1B) and qRT-PCR
(Figure S1C) showed expression of pluripotency markers; bisul-
fite sequencing showed appropriate demethylation of endoge-
nous OCT4 and NANOG promoters (Figure S1D); and qRT-PCR
demonstrated silencing of viral factors (Figure S1E). The hiPSCs
could differentiate into three germ lineages (Figures S2A and
S2B) and form teratomas in NOD-SCID mice (Figure S2A).
Furthermore, differentiation induced expression of lineage-(D) Real-time PCR of XIST expression. Ct values were normalized to IMR-90 cells
indicate standard deviations (SD) of the mean. p values were calculated with one-
Figure S4.
(E) Summary of XIST RNA FISH. n, sample size. LO, 4% oxygen; HO, 20% oxyg
(F) Three classes of XXY hiPSCs (d0, p.4). Arrows, Cot-1 holes; asterisk, XIST clspecific markers (Figure S2C) and karyotypes confirmed
a 46,XX constitution (Figure S3). These data demonstrate
successful generation of new female hiPSC lines. For XIST anal-
ysis, we used earliest possible passages (p.0–7) to circumvent
potential problems associated with long-term culture.
To examine XCI status, we performedRNA FISH and observed
one XIST cloud in 58%–84% of nuclei immediately after reprog-
ramming (p.0) (Figures 1A and 1B, Table 1). These 14 distinct
clones were derived from five different individuals, including
IMR-90 (46,XX), a 47,XXY cell line, a 46,XX ‘‘MM’’ line, and
two lines from MM’s twin daughters (‘‘TA’’ and ‘‘TB’’). An
H3K27me3 domain indicative of XIST-mediated Polycomb
recruitment was also present (Figure 1C). These findings demon-
strate XCI in a majority of cells in each line. Allele-specific anal-
yses of gene expression via single-nucleotide polymorphism
(SNP) arrays showed monoallelic expression of X-linked genes
for two hiPSC lines (Figure S4), consistent with the absence of
X reactivation after reprogramming (Tchieu et al., 2010; Cheung
et al., 2011).
However, we also observed absence of XIST in 15%–40% of
cells, raising several possibilities with respect to XCI. First, XIST
cells could represent cells that underwent X reactivation and
attained the XaXa state of pluripotent stem cells. In this scenario,
reprogramming would be accompanied by X reactivation, and
XaXi cells might represent those that spontaneously reinacti-
vated one X, as is often observed for hESCs (Higgins et al.,
2007; Dvash et al., 2010; Lengner et al., 2010). Alternatively,
the large number of XIST+ cells might indicate that X reactivation
never occurred during reprogramming and resulting hiPSCs
merely retained the Xi of parental cells, as proposed by two
previous studies (Tchieu et al., 2010; Cheung et al., 2011). In
this scenario, XIST cells would represent spontaneous loss of
XIST expression characteristic of class III hESCs (Silva et al.,
2008; Dvash et al., 2010).
To distinguish these possibilities, we performed serial RNA-
DNA FISH. We first carried out two-color RNA FISH on undena-
tured nuclei to visualize XIST and Cot-1 expression. The Cot-1
staining pattern provides an overview of nascent transcription
from a nuclear domain (Hall et al., 2002; Clemson et al., 2006;
Namekawa et al., 2010). After RNA FISH, we denatured the
samples and performed DNA FISH by using X-painting probes
to locate the X chromosomes (Figure 1B). Two types of XIST
cells were observed in all hiPSCs, irrespective of reprogramming
method (e.g., with or without VPA), passage number, and genetic
background (Table 1).
One type of XIST cells showed two Cot-1+ X chromosomes,
implying active transcription of both Xs (class I). This inferred
XaXa state suggests occurrence of X reactivation during reprog-
ramming. To determine whether percentages of XIST+ cells must
increased during cell differentiation, we placed hiPSCs in differ-
entiation conditions for 14–50 days. Indeed, XIST expression
increased (Figure 1D, Table 1; e.g., hiPS-2, hiPS-11, hiPS-12),
as would be expected of differentiating XaXa cells. We suggest(set to 1) and GAPDH, and values represent averages of triplicates. Error bars
tailed Student’s t test assuming equal variance; *p = 0.04; **p = 0.004. See also
en.
oud; double arrowheads, X chromosomes. See also Figure S5.
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Table 1. X Chromosome States in hiPSC Lines
Undifferentiated d0 Differentiated d14–d20
Sample Size (n) XIST+ Cells XIST Cells XIST Cells Sample size (n) XIST+ Cells Class Designation
hiPSC line (passage) XaXi XaXa XaXi* (Xi* in
Cot-1 hole)
hiPS-1 (p.6) 78 60% 6.4% 33% 95 55% class II predominant
hiPS-2 (p.32) 100 68% 8% 24% 153 84% class II predominant
hiPS-3 (p.14) 117 58% 7% 35% 273 54% class II predominant
hiPS-9 (p.7) 111 78% 4.5% 17% 161 91% class II predominant
hiPS-10 (p.29) 154 78% 3.2% 20% 139 80% class II predominant
hiPS-11 (p.6) 106 67% 8% 24% 287 80% class II predominant
hiPS-12 (p.6) 79 65% 14% 22% 71 72% class II predominant
hiPS-2 class III (p.50) 145 0 ND ND 80 0% class III
hiPS-9 class III (p.15) 113 0 0 100% 224 0% class III
hiPS-12 class III (p.27) 105 0 0 100% 72 0% class III
hiPS-XXY-L1 (p.7) 127 75% 7% 18% 149 91% class II predominant
hiPS-XXY-L3 (p.7) 279 71% 232 90%
hiPS-XXY-L4 (p.7) 357 66% 61 84%
hiPS-XXY-H1 (p.7) 109 81% 2.80% 17% 148 91% class II predominant
hiPS-XXY-H2 (p.7) 194 75% 285 94%
hiPS-XXY-H3 (p.7) 192 89% 205 93%
hiPS-XXY-H5 (p.7) 332 72% 134 93%
hiPS-MM 11 (p.0) 121 84% 4% 11% ND
hiPS-MM 13 (p.0) 112 76% 8% 18% ND
hiPS-TA 11 (p.0) 116 71% 6% 23% ND
hiPS-TA 12 (p.0) 138 76% 4% 20% ND
hiPS-TA 13 (p.0) 77 68% 8% 25% ND
hiPS-TB 10 (p.0) 83 74% 8% 18% ND
hiPS-TB 12 (p.0) 137 80% 5% 15% ND
hiPS-TB 13 (p.0) 85 73% 5% 22% ND
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Sex Differences in hiPSCsthat hiPS-2, hiPS-9, hiPS-10, and hiPS-11 contain a small frac-
tion of class I cells mixed with class II and III cells. Because class
I cells accounted for only 2%–14% of cells (Table 1), biallelic
expression from this subpopulation would not have been
discernible by allele-specific SNP analysis (Figure S4).
The second type of XIST cells displayed one Cot-1 X chro-
mosome, indicating X chromosome repression in spite of being
XIST (class III state) (Figure 1B). This class III phenotype resem-
bled spontaneous conversion to a class III phenotype in hESCs
(Silva et al., 2008; Dvash et al., 2010). Initially, class III cells
comprised less than one-third of each hiPSC line (Table 1).
During routine culture, three of the class II-predominant hiPSC
lines evolved to 100% class III (Table 1, hiPS-2, hiPS-9, and
hiPS-12). In the three sublines, XIST expression was absent
before and after differentiation, and one X chromosome lay
within a Cot-1 hole (Figures 1B and 1F). Two previously pub-
lished female hiPSCs lines, HD 12D-1 and JDM 6C-1, derived
from patients with Huntington’s disease and type I diabetes mel-
litus, respectively (Park et al., 2008a), were also class III, with 0%
XIST expression before and after differentiation (Figure 1E).
Examination of nascent transcription from X-linked PGK1 indi-
cated that, of XIST cells with detectable PGK1 signal, approx-
imately half showed biallelic PGK1 and half showed monoallelic78 Cell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc.expression in hiPS-9, hiPS-10, and hiPS-11 lines on day 0 (data
not shown), consistent with the idea that the XIST subpopula-
tion is a class I-III mixture.
Thus, hiPSCs and hESCs share the tendency to lose XIST
expression in culture. Once lost, XIST expression was never
regained (data not shown), though a Cot-1 hole indicative of
repetitive element silencing persisted. These data show that
our female hiPSC lines consist of a mixture of class I, II, and III
cells. The presence of XaXa cells (class I) argues that X reactiva-
tion takes place in a fraction of cells during reprogramming. The
XaXi cells (class II) indicates either that XaXa cells spontaneously
undergo reinactivation of one X or that a fraction of hiPSCs never
underwent X reactivation. Although the hiPSC lines have amixed
population, class II cells dominate at early passage. The
tendency to become class III during culture demonstrates a level
of epigenetic fluidity characteristic of female hESCs.
Effects of Oxygen and HDAC Inhibitors
Previous work showed that physiological (4%) oxygen instead of
ambient (20%) levels preserves the class I state of hESCs
(Lengner et al., 2010) and enhances reprogramming to iPSCs
(Utikal et al., 2009; Yoshida et al., 2009). We investigated
whether physiological oxygen might be beneficial for hiPSCs.
Cell Stem Cell
Sex Differences in hiPSCsHere we used a fibroblast line, derived from an 18-week-old
47,XXY fetus. It yielded 39 colonies at 20% oxygen, in contrast
to IMR-90, which typically yielded 1–6 colonies from 50,000
starting cells. Furthermore, when reprogrammed at 4% oxygen,
the XXY line produced twice asmany colonies (80) (Utikal et al.,
2009; Yoshida et al., 2009). The XXY fibroblasts behaved simi-
larly to 46,XX cells with respect to XCI, as XIST RNA was
expressed from a single X (Poplinski et al., 2010). We expanded
four clones reprogrammed in ambient oxygen (hiPS-XXY-H1,
-H2, -H3, -H5) and three in physiological oxygen (hiPS-XXY-L1,
-L3, -L4). Immunostaining and qRT-PCR confirmed expression
of pluripotency markers in all seven; each also demonstrated
EB formation and outgrowth during differentiation (Figure S5A
and data not shown). In general, hiPSCs maintained in 4%
oxygen better preserved their morphology and showed less
oxidative stress (Figure S5B). XIST RNA FISH showed that re-
programming at 4% oxygen had no effect on XIST expression
(Table 1), as the XXY lines remained predominantly class II,
with 66%–89% expressing XIST on day 0 and 84%–94% after
differentiation (Table 1, Figure 1F). The class I subpopulation
was invariably low (2.8%–7%). Class III cells were also present
in each isolate. Thus, oxygen levels have no major effect on
XIST in hiPSCs.
Previous work also showed that HDAC inhibitors promote
a more favorable epigenetic state for hESCs. Specifically, treat-
ing H9 containing a mixture of XaXa/XaXi cells resulted in
a homogeneous XaXa population capable of upregulating XIST
upon differentiation (Ware et al., 2009). To determine whether
the effects extended to hiPSCs, we treated hiPSCs with HDAC
inhibitors, sodium butyrate, and vorinostat for 5–8 passages
and examined XIST during differentiation. HDAC inhibition did
not change XIST profiles from day 0 to day 18 in any of six lines
(Table S1). All class II-predominant lines continued to show
XIST clouds in 40%–70% of cells, and three class III lines from
three distinct individuals showed no rescue of XIST expression.
Therefore, HDAC inhibition has no obvious beneficial effect for
XIST in hiPSCs.
To determine whether the effect might be specific to hESCs,
we treated two class I-predominant hESCs lines, HUES-9 and
H9 (Silva et al., 2008; Ware et al., 2009), for five passages and
examined XIST (Table S1). Consistent with previous analysis
(Ware et al., 2009), HDAC inhibition increased the number of
XaXa cells on day 0 and yielded cells with XIST clouds after
differentiation. Treatment of HUES-9 resulted in a modest
increase of XIST+ cells during differentiation but did not increase
the number of XaXa cells on day 0, as observed with H9. In
our hands, recovery after cryopreservation, general growth,
and morphology of both hESCs and hiPSCs were enhanced,
consistent with the previous report (Ware et al., 2009). We
conclude that HDAC inhibitors do not improve XIST profiles
for hiPSCs but may better rescue XIST in female hESCs (Diaz
Perez et al., 2012).
Genome-wide Transcription Profiling Reveals
Class-Specific Differences
Whether the class III state has significant biological conse-
quences is currently unknown. To address this question, we
compared genome-wide expression profiles by microarray
analysis of ten hiPSCs lines and sublines, all of which werederived from IMR-90. Hierarchical clustering revealed that all
class II-predominant cell lines showed highly correlated ex-
pression patterns among each other (Figure 2A). Furthermore,
class III lines were strongly correlated with each other. Intrigu-
ingly, class III sublines of hiPS-9 and hiPS-12 resembled each
other more than they resembled class II parents and other class
II lines. Departures from their parental lines were more dramatic
than differences for hiPSCs grown in 20% versus 4% oxygen
(hiPS-11 versus hiPS-11LO2).
Principal component analysis (PCA) supported these observa-
tions (Figures 2B and 2C). In multiple dimensions, class III hiPS-9
and hiPS-12 sublines were significantly closer to each other than
to parental class II hiPS-9 and hiPS-12 counterparts and to all
other class II lines. Interestingly, the hiPS-1 profile was closer
to class III than to other class II. This correlated with the larger
subpopulation of class III cells within hiPS-1 (33%, Table 1).
hiPS-1 may be in transition to class III. Thus, loss of XIST expres-
sion is associated with significant shifts in global expression
profiles, suggesting that the class III state is a distinct epigeno-
type that develops during culture.
Class III Association with Upregulation of
Cancer-Related Genes
To determine what genes were affected, we looked for class-
specific differences in gene expression. We used ANOVA-based
estimates of statistical significance with conservative modeling
of gene-specific intersample variance implemented in NIA Array
Analysis webtool (Sharov et al., 2005). Among genes showing
significant differential expression (FDR < 0.05), only ten coding
genes were consistently upregulated more than 2-fold in class
III compared to all class II lines (Table 2; Figure S6). Interestingly,
among the genes upregulated in class III hiPSC lines, X-linked
genes were significantly overrepresented (four out of ten genes,
p = 7 3 105). This caught our attention, given that loss of Xist
has been shown to result in partial X reactivation in murine cells
(Csankovszki et al., 2001; Zhang et al., 2007) and overexpression
of X genes has been correlated with cancer (Richardson et al.,
2006; Pageau et al., 2007).
Two of the upregulated X-linked genes, MAGEA2 and
MAGEA6, are highly expressed in cancers (Rogner et al.,
1995). Overexpression of five others has also been implicated
in cancer and metastasis, including RAB6B, a member of the
RAS oncogene family; CHP2 in ovarian tumors; ACP5 in various
cancers; and AIF1 in breast tumor growth. TCEAL3,
LOC100131199, and LOC285965 have no known function.
Thus, at least six of ten upregulated coding genes specific to
class III lines are previously identified cancer genes.
We then asked which genes were consistently downregulated
by at least 2-fold in class III cells compared to all class II samples
(Table 2; Figure S6). X-linked genes were not overrepresented
in this list, as might be expected because XIST is an X silencer.
Apart from XIST, the only other X-linked locus in the top hits
list was FTX, a noncoding gene near XIST with undefined
function (Chureau et al., 2002). Other downregulated genes of
interest were known tumor suppressors, including FN1, a fibro-
nectin involved in cell adhesion. Noncoding RNAs MALAT1
and NEAT1 (of nuclear speckles and paraspeckles associated
with cancers) were also downregulated (Ji et al., 2003; Sunwoo
et al., 2009).Cell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc. 79
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Figure 2. Class III Female hiPSCs Have Unique Global Gene Expression Patterns
(A) Pearson correlation coefficients between whole sets of gene expression levels (RMA normalization) in the ten female hiPSC samples. hiPS-2 p.9, hiPS-9 p.7,
hiPS-10 p.24, hiPS-3 p.14, hiPS-12 p.23, hiPS-11 p.16: high O2; hiPS-11 p.16: low O2; hiPS-9 p.19 c.III; hiPS-12 p.30 c.III.
(B and C) PCA of gene expression patterns in indicated samples. Plot of component loadings shows relations of each microarray sample (RMA normalization) in
PC1 versus PC2 (B) and of PC2 versus PC3 (C). Class II to III conversion indicated by arrows.
(D and E) Expression levels for genes downregulated (D) and upregulated (E) in class III samples. Shown are top genes with highest correlation (D) or anti-
correlation (E) to XIST expression, among those that are differentially expressed in at least six out of eight class II versus class III lines. See also Figure S6.
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Table 2. Genes with Greatest Expression Change in Class III hiPSCs
Gene Name Description Chr. FDR
Genes Showing Greatest Upregulation
MAGEA6 melanoma antigen family A, 6 X 0
MAGEA2 /// MAGEA2B melanoma antigen family A, 2 /// melanoma antigen family A, 2B X 0
ACP5 acid phosphatase 5, tartrate resistant 19 0
TCEAL3 transcription elongation factor A (SII)-like 3 X 0.0001
HDHD1A haloacid dehalogenase-like hydrolase domain containing 1A X 0.0007
RAB6B RAB6B, member RAS oncogene family 3 0.0017
AIF1 allograft inflammatory factor 1 6 0.0082
CHP2 calcineurin B homologous protein 2 16 0.0111
LOC285965 hypothetical protein LOC285965 7 0.0231
LOC100131199 LOC100131199 transmembrane protein 178-like (Homo sapiens) 7 0.0475
Genes Showing Greatest Downregulation
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (nonprotein coding) 11 0
XIST X (inactive)-specific transcript (nonprotein coding) X 0
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A 5 0
AI380514.1 tg01e02.x1 NCI_CGAP_CLL1Homo sapiens cDNA clone IMAGE:2107514 3-, mRNA sequence 2 0
NAA25 N(alpha)-acetyltransferase 25, NatB auxiliary subunit 12 0
MED17 mediator complex subunit 17 11 0
FARSB phenylalanyl-tRNA synthetase, beta subunit 2 0
AA524609.1 nh34c11.s1 NCI_CGAP_Pr3 Homo sapiens cDNA clone IMAGE:954260 similar
to contains Alu repetitive element;, mRNA sequence
/ 0
BC020935.1 similar to otoconin 90, clone IMAGE:4277593 13 0.0001
BF223214.1 7q30f03.x1 NCI_CGAP_GC6 Homo sapiens cDNA clone IMAGE:3699965 3-, mRNA sequence 6 0.0003
AI684643.1 wa84h10.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2302915 3-,
mRNA sequence
12 0.0005
FTX FTX, NCRNA00182 nonprotein coding RNA 182 (Homo sapiens) X 0.0006
FN1 fibronectin 1 2 0.0007
LOC649305 hypothetical LOC649305 8 0.0008
AW135003.1 UI-H-BI1-abt-c-08-0-UI.s1 NCI_CGAP_Sub3 Homo sapiens cDNA clone
IMAGE:2712951 3-, mRNA sequence
11 0.0028
FST follistatin 5 0.0033
NPPB natriuretic peptide precursor B 1 0.0058
AV699781.1 AV699781 GKC Homo sapiens cDNA clone GKCEKC01 3-, mRNA sequence / 0.0061
FNBP4 formin binding protein 4 11 0.0063
AW197431.1 xm39b03.x1 NCI_CGAP_GC6 Homo sapiens cDNA clone IMAGE:2686541 3- similar
to contains element KER repetitive element; mRNA sequence
12 0.0064
IGFBP5 insulin-like growth factor binding protein 5 2 0.0167
NEAT1 NEAT1 nuclear paraspeckle assembly transcript 1 (nonprotein coding) (Homo sapiens) 11 0.0211
CER1 cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis) 9 0.0265
GAD1 glutamate decarboxylase 1 (brain, 67 kDa) 2 0.0484
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specific associations with cancer genes and raises the question
of how many of the class III changes could be attributed to or
strongly correlated with loss of XIST. To address this, we identi-
fied genes whose expression levels had highest Pearson corre-
lation coefficients with XIST levels across all samples. We
included genes that were upregulated in all class III lines
compared to at least six of eight class II lines. Several hundred
met these criteria (see Table S2 for complete list), of which 30
with greatest correlation are shown in Table 3. Intersecting thelist of XIST-correlated genes with known cancer genes from
MSKCC CancerGenes resource (Higgins et al., 2007) revealed
nine tumor suppressors (CDC14B, CDK6, CNOT7, IDH1,
IGFBP5, PCDH10, PLXNC1, RBBP4, STK4) and seven onco-
genes (BCL11A, CHD1L, FGFR1, FUS, FYN, RAB12, SOS1)
that were differentially expressed between class II and class III.
Genes with highest correlation with XIST include SEMA6A,
MALAT1, and FTX and genes for oxidative stress response,
COX1 (R = 0.94) and PRDX2 (R = 0.838) (Figure 2D, Table 3).
Also highly correlated were members of the Mediator complexCell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc. 81
Table 3. Genes with Greatest Expression Correlation with XIST
Gene Description Chr. FDR Corr. # Chip
Positive Correlation
XIST X (inactive)-specific transcript (nonprotein coding) X 0 1 8
ZNF207 zinc finger protein 207 17 0.0034 0.9446 8
COX1 cytochrome c oxidase I MT 0 0.9444 8
NAA25 N(alpha)-acetyltransferase 25, NatB auxiliary subunit 12 0 0.9423 8
TRIM4 tripartite motif-containing 4 7 0.0001 0.9416 7
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic
domain, (semaphorin) 6A
5 0 0.9415 8
AV699781.1 AV738585 CB Homo sapiens cDNA clone CBFAWD05 5-, mRNA
sequence
/ 0.0258 0.9396 8
AA524609.1 nh34c11.s1 NCI_CGAP_Pr3 Homo sapiens cDNA clone
IMAGE:954260 similar to contains Alu repetitive element; mRNA
sequence
/ 0 0.9384 8
HNRNPA1 /// LOC728844 heterogeneous nuclear ribonucleoprotein A1 /// hypothetical
LOC728844
12 0.0044 0.9370 8
N72610 za46h03.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA
clone IMAGE:295637 3-, mRNA sequence
/ 0.0287 0.9270 6
AI247478 qh56c08.x1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens
cDNA clone IMAGE:1848686 3- similar to contains Alu repetitive
element; contains element PTR5 repetitive element; mRNA sequence
8 0.0007 0.9261 4
BE503070 hz83b02.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone
IMAGE:3214539 3-, mRNA sequence
5 0.0001 0.9204 8
MDN1 MDN1, midasin homolog (yeast) 6 0 0.9120 8
AI806781 wf15b12.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone
IMAGE:2350655 3-, mRNA sequence
17 0 0.9092 8
BG281679 602402364F1 NIH_MGC_20 Homo sapiens cDNA clone
IMAGE:4544871 5-, mRNA sequence
/ 0.0056 0.9090 4
BF223214 7q30f03.x1 NCI_CGAP_GC6 Homo sapiens cDNA clone
IMAGE:3699965 3-, mRNA sequence
6 0.0003 0.9081 8
AI539426 te46d04.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone
IMAGE:2089735 3-, mRNA sequence
12 0.0039 0.9035 8
AI380514 tg01e02.x1 NCI_CGAP_CLL1 Homo sapiens cDNA clone
IMAGE:2107514 3-, mRNA sequence
2 0 0.9027 8
W86781 zh64a03.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens
cDNA clone IMAGE:416812 3-, mRNA sequence
20 0.0003 0.9020 8
AI056872 oz03e12.x1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens
cDNA clone IMAGE:1674286 3-, mRNA sequence
6 0.0007 0.9018 1
MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 12 0.0035 0.9016 8
FUS fusion (involved in t(12;16) in malignant liposarcoma) 16 0.0012 0.9016 8
AA398740 zt75f06.s1 Soares_testis_NHT Homo sapiens cDNA clone
IMAGE:728195 3-, mRNA sequence
1 0.0003 0.9016 7
CHD1L chromodomain helicase DNA binding protein 1-like 1 0.0006 0.9006 8
FTX NCRNA00182 non-protein coding RNA 182 (Homo sapiens) X 0.0006 0.9005 8
CHPT1 choline phosphotransferase 1 12 0.0023 0.8984 3
AI367034.1 qq40f01.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone
IMAGE:1935001 3- similar to contains Alu repetitive element; mRNA
sequence
2 0.0081 0.8958 8
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (nonprotein
coding)
11 0 0.8948 8
AA436194.1 zv22f03.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone
IMAGE:754397 3- similar to contains Alu repetitive element;contains
element PTR7 repetitive element; mRNA sequence
4 0.0434 0.8948 8
MED17 mediator complex subunit 17 11 0 0.8939 8
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Table 3. Continued
Gene Description Chr. FDR Corr. # Chip
Negative Correlation
HDHD1A haloacid dehalogenase-like hydrolase domain containing 1A X 0.0007 0.9824 8
MAGEA2 /// MAGEA2B melanoma antigen family A, 2 /// melanoma antigen family A, 2B X 0 0.9801 3
TCEAL3 transcription elongation factor A (SII)-like 3 X 0.0001 0.9560 8
AIF1 allograft inflammatory factor 1 6 0.0082 0.9557 0
RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) 11 0.0211 0.9533 7
ACP5 acid phosphatase 5, tartrate resistant 19 0 0.9490 0
SDCCAG8 serologically defined colon cancer antigen 8 1 0.0017 0.9474 1
NXT2 nuclear transport factor 2-like export factor 2 X 0.0014 0.9461 0
MAGEA6 melanoma antigen family A, 6 X 0 0.9437 0
CHP2 calcineurin B homologous protein 2 16 0.0111 0.9284 3
CSAG2 /// CSAG3 CSAG family, member 2 /// CSAG family, member 3 X 0 0.9256 0
C20orf94 chromosome 20 open reading frame 94 20 0.0178 0.9185 3
ZNF264 zinc finger protein 264 19 0.0078 0.9169 7
RAB6B RAB6B, member RAS oncogene family 3 0.0017 0.9138 2
C1orf77 chromosome 1 open reading frame 77 1 0.0035 0.9127 8
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 1 0.003 0.9112 3
MBNL3 muscleblind-like 3 (Drosophila) (Homo sapiens) X 0.0035 0.9096 2
ZNF768 zinc finger protein 768 16 0.0064 0.9038 7
LOC284242 hypothetical protein LOC284242 18 0.0191 0.9036 7
PRPS1 phosphoribosyl pyrophosphate synthetase 1 X 0.0173 0.9019 8
REPS2 RALBP1 associated Eps domain containing 2 X 0.0197 0.9009 6
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promoters of active genes in pluripotent cells, and MLL2,
a histone 3 lysine-4 (H3K4) methyltransferase responsible for
bulk methylation of H3K4me3 associated with transcriptional
activation. Using DAVID Bioinformatics Resource (Huang et al.,
2009), we observed significant enrichment for genes involved
in transcription (FDR = 0.001), transcriptional repression (FDR =
0.0017), and transcriptional regulation (FDR = 6.02 3 104).
DAVID analysis of Table S2 also confirmed enrichment for
many genes involved in RNA processing (FDR = 0.006), splicing
(FDR = 0.054), binding (FDR = 0.034) stability, and export (e.g.,
FUS, HNRNPA1, SFPQ, HNRNPD, SFRS15, SFRS4).
The same analysis was applied to genes whose expression
levels had the greatest anticorrelation (negative Pearson correla-
tion coefficients) with XIST levels across all samples (Table 3;
complete gene list in Table S3), of which 12with highest negative
Pearson correlation coefficients are plotted in Figure 2E. There
was considerable overlap between Tables S2A and S3B, and
X-linked genes were significantly overrepresented (p = 2 3
108, for 9 of 21 genes being X-linked in Table 3). Again, cancer
genes were also highly represented. In addition to those in
Table 2, CSAG2, NUCKS1, REPS2, MTA2, RAB6B, RAP2C,
and VAV1 showed anticorrelation with XIST. Oncogenes
MAGE2A (R =0.980) andMAGE6A (R =0.944) showed espe-
cially high correlation. DAVID analysis of Table S3 yielded no
significant enrichment for any group of genes. Notably, onco-
genes as a general class were not significantly enriched. Taken
together, these argue for enriched expression only of oncogenes
residing on the X, resulting from loss of XIST-mediated suppres-
sion in cis. We conclude that loss of XIST expression is stronglycorrelated with X gene overexpression, hyperexpression of
select X-linked oncogenes, and repression of select tumor
suppressors.
Male and Female Differences in hiPSC Quality
Because male cells do not undergo XCI, male hiPSCs cannot be
subclassified by XIST expression. However, the strong genome-
wide positive and negative correlations identified above for
female hiPSCs might be used in lieu of XIST to address male
hiPSC quality. Could male hiPSCs be subcategorized on the
basis of genome-wide expression profiles? Do some male
hiPSCs exhibit aberrant expression of cancer genes? To
address these questions, we analyzed gene expression profiles
of published male and female hiPSCs derived from normal fibro-
blasts by reprogramming with either virally introduced factors,
modified RNA, or direct protein delivery (Maherali et al., 2008;
Park et al., 2008b; Kim et al., 2009; Jia et al., 2010; Mayshar
et al., 2010; Tchieu et al., 2010; Warren et al., 2010). We also
queried whether variability occurred in hESC lines (Westfall
et al., 2008; Chen et al., 2011) and compared male hiPSC and
female hESC profiles to our female hiPSCs, including a low-
oxygen line (hiPS-2 cIII LO) and two disease-model hiPSC lines
(12D-1, 6C-1) created elsewhere but passaged in our laboratory
(Park et al., 2008a). Our diverse sampling therefore tested cell
lines of distinct provenance, with fibroblasts derived from
multiple individuals and hiPSCs created in 12 different labs.
We first performed hierarchical clustering and PCA loading
analyses. Because hiPSC lines are known to have a tendency
to cluster by laboratory of origin (Guenther et al., 2010; Laurent
et al., 2011) and because variations could arise from biasesCell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc. 83
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Figure 3. Microarray Analyses of Male versus Female hiPSCs and hESCs
(A and B) PCA shown in two dimensions for ComBat-corrected (A) and uncorrected (B) samples. See Table S4 for list of samples, GEO numbers, PubMed ID, and
abbreviations. Class III hiPSCs from this study (L3) in green; L3 LO, hiPS-2 c.III in low oxygen p.50; L3-6, hiPS-6C-1 c.III p. 28; L3-12, hiPS-12D-1 c.III p.28. Blue,
male hiPSCs; pink, female hiPSCs; black, female hESCs.
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Sex Differences in hiPSCsbetween microarray batches (‘‘batch effects’’), we analyzed the
data without in silico correction of batch effects or with correc-
tion via the ComBat method (Figures 3A and 3B; Johnson
et al., 2007). Several patterns emerged with either method. First,
there is a tendency for each type of cell line to cluster together,
irrespective of lab origin. For example, female hESCs clustered
together (black), as did female hiPSCs (pink) and male hiPSCs
(blue). Furthermore, class III female lines (green) grouped
together but away from female hiPSCs and hESCs. In general,
female hiPSC lines showed greater variation among one another
than did male hiPSC lines among themselves (blue male lines
versus pink female lines; Figures 3A and 3B). Interestingly, while
male hiPSCs tend to group together apart from female hiPSCs,
RNA-reprogrammed male lines (R4, R5) (Warren et al., 2010)
appeared to better resemble female hESCs and hiPSCs. The
secondarily reprogrammed male hiPSC line (H4-2) was also set
apart from other male hiPSCs (most evident with ComBat
correction; Figure 3A). These differences pertained to cell lines
derived not only in different laboratories but also within any given
laboratory, as evidenced by loose groupings observed in
multiple PCA dimensions (Figures 3A and 3B).
Given a strong positive association between XIST loss and
overexpression of select X-linked oncogenes (Tables 2, 3, and
S4), we next askedwhethermolecular signatures ofmale hiPSCs
could be compared against those of female hiPSCs to infer stem
cell quality. For the genes differentially expressed in class III
versus II (Table 2), we evaluated expression profiles in female
hiPSCs, male hiPSCs, and female hESCs and compared them
to the average of class III lines, hiPS-9 and hiPS-12 (Figure 3C,
L3 [cIII]), as the basis for comparison. As expected, all three class
III lines (green) showed low XIST expression, whereas class II
lines of various provenance (pink) showed significantly more
XIST expression. The dark red values for male hiPSCs (blue)
were consistent with low-level XIST expression known to occur
in male mouse embryonic stem cells (Beard et al., 1995), consis-
tent with their successful reprogramming.
In general, male hiPSC expression profiles resembled those of
class II female hiPSCs (except XIST levels were lower than in
class II lines but higher than in class III lines, consistent with
pinpoint XIST expression in undifferentiated ESCs of mice)
(Figure 3C). The male profiles, however, significantly deviated
from those of the hiPS-9/hiPS-12 class III average. For example,
male hiPSCs lines generally did not show increased expression
of the oncogenes upregulated in class III lines (e.g., MAGEA2,
MAGEA6, RAB6B, TCEAL3, and ACP5). Main exceptions were
male D6(3) and D6(32), which displayed increased MAGEA2
and MAGEA6 expression, and the secondarily reprogrammed
male lines (shown as an average, H4-2), which showed
increased expression of many genes upregulated in class III lines
(e.g., TCEAL3, ACP5, CHP2, RAB6B; Table 3). By contrast, the
additional class III female lines exhibited a trend toward greater
expression of the most correlated marker genes from Table 2.
For example, L3(cIII)LO (hiPS-2 c.III grown in low oxygen) and
L3(cIII)Dis (disease lines, hiPS 6C-1 and 12D-1) had similarly(C) Expression heatmaps normalized to hiPS-9 and hiPS-12 c.III average (e
hiPSCs (Table 2). L3 (cIII), hiPS-9, hiPS-12 c.III; L3 (cIII) LO, hiPS-2 c.III; L3 (c
samples.
(D) XIST expression in indicated lines plotted against correlation of expression pincreased expression of TCEAL3, RAB6B, LOC285965, and
CHP2.
Even among class II female lines, casual examination hinted
at a correlation between degree of XIST expression and likeness
to the class III profile. For instance, hiPS-1 (L3-1, Figure 3C),
shown above to be a class II-III intermediate (Figures 2B and
2C), resembled the class III profile (Figure 3C). This suspicion
was confirmed by direct quantitative analysis of profile similar-
ities calculated as Pearson correlation coefficients of expression
values on the set of genes differentially expressed in class III
(Table 2), excluding XIST itself. This analysis revealed a trend
of monotonic decrease with increasing level of XIST expression
(Figure 3D). Two loose groupings of female hiPSCs were
apparent. Cell lines with highest XIST expression occupied
the bottom right region of the plot, demonstrating the highest
dissimilarity to class III. Those with intermediate XIST ex-
pression were located in the center (e.g., hiPS-1 [a.k.a. L3-1]),
demonstrating a drift toward the class III reference in the top-
left corner.
Taken together, these results argue that upregulation of
X-linked oncogenes and other loci revealed in Tables 2 and 3
is a property of female hiPSCs when they lose XIST expression.
Though not generally a feature of male hiPSCs, secondarily
reprogrammed male lines may more closely resemble class III
female lines. We believe that expression differences in class III
lines are due to epigenetic change rather than to genomic alter-
ations, as microarray-based comparative genomic hybridization
(CGH) on paired sets of class II and III lines revealed no gross
copy number changes (Figure S7). No deletions within the XIST
locus were observed in each case. Thus, we demonstrate that
hiPSCs of both male and female origin could be evaluated by
comparison to the deviant class III profiles.
Loss of XIST Results in Accelerated Growth In Vitro
and Poor Differentiation In Vivo
Here we tested whether resemblance to class III has functional
consequences. In light of increased oncogene expression, we
asked whether class III lines grow faster in culture. Wemeasured
growth rates of multiple undifferentiated class II and III cells in
four independent experiments over 20–35 days and plotted
numbers of cells (Figures 4A and 4B) and colonies (Figure 4C).
In multiple replicates, class III hiPSC lines generally exhibited
a shorter doubling time than their class II parents and other class
II lines (Figures 4A and 4B). They also grew more quickly than
male hiPSCs. This was the case in high and physiological oxygen
conditions. Interestingly, hiPS-1—the class II-III transitional cell
line—exhibited a growth rate more similar to class III cells (Fig-
ure 4A), thus correlating with its class III-like expression profiles
(Figures 3A and 3C). Other transitional lines (identified by fewer
XIST+ clouds) also displayed faster growth rates than their class
II parents (compare hiPS-12 p.28 to hiPS-12 p.32). Faster growth
rates did not appear to be a consequence of adaptation to
culture, as we tested class II cell lines (hiPS-2, hiPS-11,
hiPS-12) at early (p.14) and later (p.32) passages and foundxpression set as 0). Shown are genes up- and downregulated in class III
III) Dis., hiPS 6C-1, 12D-1 c.III. Averages shown for duplicate and triplicate
attern across differentially expressed genes.
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Figure 4. Comparative In Vitro Growth Rates and In Vivo Differentiation
(A) Growth profiles for indicated hiPSC lines in ambient oxygen. Doubling times calculated from line equations. One colony for each line was mechanically
passaged and plated in ten replicate, MEF-coated wells. Cells were trypsinized and counted. Averages shown. Percentages of XIST+ nuclei at the end of the
experiment shown. n, sample size; N.D., not determined. Two biological replicates performed; similar results; one shown.
(B) Growth profiles for indicated lines in physiological oxygen. Three colonies for each line were plated in quadruplicate onMEF-coated plates, then processed as
in (A).
(C) Growth differences as a function of passage number at ambient or physiological oxygen. Average values shown.
(D) Teratomas from matched class II-III sublines of hiPS-2 and hiPS-12.
(E) Representative histologic sections of class II and III teratomas.
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Interestingly, we also observed that class III lines recovered
faster after routine passaging, as these lines typically yielded
greater colony numbers and larger colony sizes 1 day after
passaging when compared to class II lines and male hiPSCs.
We next investigated the ability of class III cells to form tera-
tomas. In general, hiPSCs are known to form teratomas when
injected into immunocompromised mice. Although both class II
and III lines could do so, their in vivo differentiation capacities
were markedly different (Figures 4D and 4E). Class II teratomas
showed prominent differentiation into structures recapitulating
adult organs and tissues, such as cartilage and small intestine,
including a range of cell types found in mature intestine including
mucin-producing epithelial cells and Paneth cells, secondary
organization into villi, and investing layers of circular and longitu-
dinal smooth muscle (Figures 4D, 4E, and S2A). Intriguingly, all
teratomas derived from four representative class II sublines
(hiPS-2, hiPS-10, hiPS-11, and hiPS-12) formed solid masses
(5 of 5); by contrast, teratomas derived from the matched class
III sublines (hiPS-2 and hiPS-12) and disease model line (6C-1)
were all cystic (11 of 11), with the cysts lined by simple epithelia
and undifferentiated mesenchymal tissue, with little to no differ-
entiated cell types (Figures 4D and 4E). Two of the 11 cystic
teratomas had small solid masses with a low degree of differen-
tiation into all three germ layers. Notably, one prior report found
that male hESCs formed solid teratomas but one female hESCs
line with unknown XIST expression status produced cystic tera-
tomas (Mikkola et al., 2006). Our observed differences between
matched class II-III lines argue that class III cells may generally
form poorly differentiated teratomas of cystic nature. The poor
differentiation is consistent with a cancer-like state. On the basis
of these observations, we suggest that XCI class designations of
female hiPSCs may have practical implications for stem cell
therapy.
DISCUSSION
Here, we have studied genome-wide expression profiles of
multiple new and existing hiPSC lines and shown that the XCI
marker XIST RNA can be used as a readout to assess one aspect
of female hiPSC quality. The gene expression profiles have iden-
tified molecular signatures that distinguish XIST+ (class II) and
XIST (class III) female hiPSC lines. Loss of XIST expression in
class III cells is associated with upregulation of oncogenes,
several of which are X linked, and downregulation of several
tumor suppressors. We do not know whether loss of XIST is
directly responsible for these expression differences. An alterna-
tive possibility is that conditions that lead to loss of XIST expres-
sion cause other changes genome-wide. In either case, we
presume that these changes are generally undesirable and can
therefore be used as additional benchmarks of hiPSC quality.
Indeed, the class III changes correlate with faster growth in
culture. Notably, these changes are not generally observed for
male hiPSC lines. We also observed differences in differentiation
in vivo, as shown by formation of predominantly cystic, poorly
differentiated teratomas in immunocompromised mice.
These data argue for class- and sex-specific differences in
epigenetic stability of hiPSCs that depend in large part on the
ability to maintain XCI. One major implication is that the epige-netic state of female hiPSCs may be more difficult to maintain
in culture, at least by current protocols. Neither physiological
oxygen nor HDAC inhibitors offered any advantage nor more
efficient X reactivation. Several recent works suggest that
hiPSCs are not equivalent to the more extensively reprog-
rammed ‘‘naive’’ female hiPSCs, which apparently contain two
Xa andmay therefore represent the best model for X reactivation
in hiPSCs (Hanna et al., 2010; Pomp et al., 2011; Wang et al.,
2011). However, it is not clear whether these naive hiPSCs
contain a pure population of class I cells or rather a mixture of
class I-III cells. The epigenetic stability of XIST after extended
culture is also uncertain. Better protocols are needed in order
to avoid the potentially unfavorable genome-wide changes
seen in many female hiPSC lines.
Another major implication may be that class III female hiPSC
lines are best avoided for in vivo human therapy because of (1)
the upregulation of some X-linked cancer genes, (2) faster-
than-normal growth rates ex vivo, and (3) poor differentiation
potential in vivo. Some hiPSC lines may evolve into the class III
state more readily than others, perhaps because of underlying
genetic and copy number variation between parental cell lines
or the number of viral OSKM integrations. Although we do not
know whether upregulation of X-linked and other oncogenes is
a direct consequence of XIST repression, we surmise that the
absence of XIST in class III lines may promote reactivation of
undesirable X-linked genes, given recent work showing that
conditionally deleting Xist on Xi of mouse somatic cells and
loss of XIST in hESCs can result in piecemeal X reactivation
(Csankovszki et al., 2001; Shen et al., 2008; Diaz Perez et al.,
2012). If X reactivation occurs in these lines, they do not occur
on all X genes at once (one X still resides in a Cot-1 hole). Never-
theless, the possibility of general X reactivation over time should
present significant concern and urge caution in using some
female hiPSC lines in cell regeneration programs. We therefore
encourage the use of XCI markers as a benchmark to assess
quality of all female hiPSCs and, by inference, hESC lines. Going
forward, we suggest that XIST expression in combination with
differentiation potential be used to assess stem cell quality.
EXPERIMENTAL PROCEDURES
hiPSC Culture and Derivation
IMR-90 fibroblast line (ATCC; CCL-186) was cultured in EMEM medium with
10% FBS and XXY line (Corielle GM03102) with 15% FBS. Human iPSCs
were maintained on irradiated MEFs with hESC medium (DMEM/F12, 10%
knockout serum replacement [Invitrogen], L-glutamine, nonessential amino
acids, 2-mercaptoethanol, penicillin/streptomycin, and 10 mg bFGF). For
hiPSC derivation, 105 fibroblasts were infected with retrovirus (pEYK cassette
with 4F) (Park et al., 2008a) at ambient oxygen, then 48 hr later transferred to
MEF-coated plates at either ambient or 4% oxygen. MM, TA, and TB fibro-
blasts were reprogrammed with the tet-inducible lentiviral STEMCCA and
rtTA (without MEFs, no VPA during reprogramming or ROCK inihibitor). For
hiPSC-1, hiPSC-2, hiPSC-3, hiPSC-9, hiPSC-10, hiPSC-11, and hiPSC-12,
cells were treated with 1 mM VPA for 7 days (10 days for XXY lines), and colo-
nies were picked 1 month after infection. Use of VPA did not impact occur-
rence of class I, II, or III cells, as MM, TB, and TA lines were reprogrammed
without it. ROCK inhibitor Y-27632 (Calbiochem) was used for the first
2 days during the first two passages and after thawing cells. All hiPSCs were
passaged manually. For HDACi treatment, sodium butyrate (0.1 mM; Sigma)
and vorinostat (400 nM; Cayman) were freshly diluted and added daily. For
cell growth experiments, colonies were split by cell rollers (Invitrogen) and
one colony (about ten clumps) or three colonies for each line were transferredCell Stem Cell 11, 75–90, July 6, 2012 ª2012 Elsevier Inc. 87
Cell Stem Cell
Sex Differences in hiPSCsto one well of a 96-well plate (one well of 12-well plate for three colonies). Cells
were plated in triplicate. After day 7, duplicate wells containing three to five
colonies were transferred to two wells (12-well plate). Cells were harvested
weekly. Half the culture was counted and the other half passaged onto
MEF-coated wells for four to six passages. Colony number was determined
by counting undifferentiated colonies at each passage. The derivation of
hiPSCs from fibroblasts obtained from ATCC and Corielle (lacking patient
identification) does not require a human subjects oversight committee.
In Vitro and In Vivo Differentiation of hiPSCs
Human iPSC colonies were dislodged with cell scraper and transferred to low
attachment 6-well plates containing hESC differentiation media (hiPSC media
without b-FGF with 20% FBS). EBs were transferred to gelatin-coated plates
(day 7) and cultured for additional 8–14 days. For EB germ lineage testing,
hiPSCs were dispersed then grown in ultra-low attachment 6-well plates
(Nunc) in hESC media without b-FGF supplemented with 1% FBS for
19 days. EBs were fixed in PBS with 4% paraformaldehyde (PFA), pelleted
in low-melt agarose, paraffin embedded, sectioned (5 mm), and then stained
with H&E. For teratoma injections, one to two 10 cm plates of confluent
hiPSCs (no MEFs) were pelleted and mixed with equal volume of 23 Matrigel
(200 ml/injection). Tumors appeared 6–12 weeks after injection and were
dissected and fixed overnight with 4% PFA, then sectioned and stained with
H&E. These injectionswere performedwith oversight of the Institutional Animal
Care and Use Committee (IACUC) at Massachusetts General Hospital.
Microarray Experiments
Total RNA isolated with Trizol and converted to cDNA via NuGEN Ovation V2
Amplification system. cDNA was hybridized to Affymetrix Human Genome
U133 Plus 2.0 Arrays (Microarray Core Facility, Dana Farber Cancer Institute).
Samples: hiPS-1 p.31, hiPS-2 p.9, hiPS-3 p.14, hiPS-9 p.7, hiPS-10 p.24,
hiPS-11 p.16, hiPS-11 p.16 (4% O2), hiPS-12 p.23 (4% O2), hiPS-9 p.17
(XIST), and hiPS-12 p.30 (XIST).
Microarray expression data were normalized by RMA (Irizarry et al., 2003).
Hierarchical clustering and PCA were performed on the total sets of RMA
expression values. MAS5 (Liu et al., 2002) and MBEI (Li and Hung Wong,
2001) normalization produced similar results. For the analysis of differential
expression, we used the estimates of false discovery rate (FDR; ANOVA-
based) with variance adjustment, implemented in NIA Array Analysis (Sharov
et al., 2005). The tool was used with default parameters, except for z score
threshold for outliers set to 10,000. The definition of differentially expressed
genes was based on the combination of high statistical significance (FDR
cutoff 0.05) and themagnitude of expression change.When overall expression
was consistent between samples and the two compared groups corre-
sponded to tight clusters, differentially expressed transcripts were defined
with FDR < 0.05 and R2-fold change between group expression means. In
the absence of tight clustering (class II female samples), differentially ex-
pressed transcripts were defined based on FDR cutoffs (FDR < 0.05) and n
(individual samples that consistently showed at least 2-fold expression change
compared to other group). For the eight samples of class II, we used the strict
cutoff of n = 8 (all samples) and a more relaxed cutoff of n = 6. Correlation with
XIST expression was measured by Pearson correlation coefficient calculated
for the expression values. ComBatmethod for the compensation of microarray
batch effects (Johnson et al., 2007) was run with default parameters on RMA
expression values in the set of Affymetrix microarrays for different cell lines.
DAVID functional annotation tool (Huang et al., 2009) was run online on the
extended sets of differentially expressed genes.
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The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
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